A recent study published in CA: A Cancer Journal for Clinicians, a peer-review journal of the American Cancer Society, links excess body weight to approximately 4 percent of cancers worldwide.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
A group of researchers with UCLA developed a spray gel that contains immune-stimulating drugs.
The benefits of statins in reducing the odds of heart attacks and strokes far outweigh any risks of side effects, according to a scientific statement released by the American Heart Association.
Axovant Sciences’ Phase II trial of nelotanserin for the treatment of REM sleep behavior disorder in patients with Lewy body dementia failed to meet the experimental drug’s primary efficacy endpoint.
A global coalition set up to fight disease epidemics is investing up to $8.4 million to develop a synthetic vaccine system that could be tailor-made to fight multiple pathogens such as flu, Ebola, Marburg and rabies.
Generon Presents Positive Phase III Results Of F-627 In Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Generon BioMed Holding Ltd. announced at the annual San Antonio Breast Cancer Symposium (SABCS) positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor protein, designed using Generon’s Dikine technology platform.
Orchard Therapeutics is developing a suite of autologous ex-vivo lentiviral gene therapies to correct a rare autoimmune disorder.
AstraZeneca’s immunotherapy treatment Imfinzi did not meet the main goals in a late-stage study for advanced head & neck cancer.
Supernus Pharmaceuticals’ experimental drug for attention deficit hyperactivity disorder met the main goal of reducing symptoms in affected children from 6 to 11 years of age in two late-stage studies.